Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBW251 in bronchiectasis
NCT04396366Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Icenticaftor in bronchiectasis, sponsored by Novartis. Started Feb 2021; status: terminated.
02
Drugs
Icenticaftor
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT04396366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396366.